Live
- Ashutosh Gowariker to lead International Jury at IFFI 2024
- The global challenges of greener aviation
- Shreyas Media secures exclusive advertising rights for ‘MahaKumbh Mela 2025’
- Experience the journey of art
- Seven iconic ghats undergo makeover for Mahakumbh
- Smog engulfs capital with ‘severe’ air quality
- Slur against HDK wrong, Zameer will be corrected: K’taka Cong
- Himalayan Echoes Literature Festival returns to Nainital with a focus on art, environment, and culture
- Taking Off: Solo travelling as a minor
- MVA will win over 160 seats, form govt in Maha: Shivakumar
Generic glaucoma drug to halt myopia progression
A generic glaucoma drug has been shown to halt the progression of myopia (nearsightedness), potentially offering rapid approval for a new treatment of an incurable condition. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md. Scientists induced myopia in guinea pig eyes then treated the eyes wit
A generic glaucoma drug has been shown to halt the progression of myopia (nearsightedness), potentially offering rapid approval for a new treatment of an incurable condition. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md. Scientists induced myopia in guinea pig eyes then treated the eyes with artificial tears or topical latanoprost, a drug that is commonly used to treat glaucoma. Lantanoprost significantly slowed myopia progression over three months. Myopia is expected to affect half of the world’s population by 2050. Though correctable through glasses, it is known to lead to blinding conditions including cataracts, glaucoma and retinal detachments. Getting regulatory approval to use existing drugs for new conditions is often years faster than creating a new drug.
